Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

Phase 3 trials and their relationship to outcome.  These data show that the cure rate among patients harboring BI isolates was significantly lower than those with non-BI strains (86.5% vs. 94.3%, p=0.0006) and that the recurrence rate was significantly higher for those with the BI strain versus the non-BI strains (27.3% vs. 16.6%, p=0.003).  In the trials, the BI strain of Clostridium difficile was the major strain type (39%) in North America but the BI strain was not nearly as frequent in Europe (10%). In the non-BI group recurrence rates were significantly lower in  patients treated with fidaxomicin versus patients treated with vancomcyin (8.4% vs. 25.3%, p<0.001).  In the BI group fidaxomicin showed a clinically meaningful 25% reduction in recurrence rates compared to vancomycin (23.3% vs 31.2%).Clinical investigator, Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented analyses on a bedside scoring system for assessing CDI risk factors. There is currently no validated bedside risk assessment tool to categorize patients or predict CDI cure or recurrence. Using data from Optimer's first fidaxomicin Phase 3 trial, researchers evaluated a scoring system composed of five simple patient risk factors:  Age, Temperature (T), Leukocytosis (WBC), Albumin (Alb), and Concomitant Systemic Antibiotics (SA).  These five bedside risk factors were combined to correlate with CDI cure, recurrence, and global cure.  Dr. Miller recommended that this scoring system should be validated on other databases of CDI patients in order to assist in predicting CDI cure, recurrence, morbidity, and mortality.  

For a complete list of posters, please visit the Resources page on our website at: www.optimerpharma.com

Fidaxomicin Clinica
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Holomic is expanding ... debut of its fluorescent immunoassay reader, the HRDR-300, ... meeting in Chicago, July 28-31, 2014. Available in ... the HRDR-300 is a highly sensitive, low-cost fluorescent ... fluorescent lateral flow immunoassays with high sensitivity and ...
(Date:7/22/2014)... Biofeedback – When a behavioral problem ... medication to best treat it can become a matter ... electroencephalography (EEG) can help predict which medicine will offer ... adverse drug events. , The article “Medication Prediction ... issue of the journal Biofeedback offers evidence that quantitative ...
(Date:7/22/2014)... 22, 2014 Dr. Williams says, “Bush ... have recognized that the greatest health care system in ... often needlessly deadly while trying to serve the public. ... seeking to transform an enormous system that none of ... in his continuing series of Open Letters ( http://is.gd/wdU2CM ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 With ... simple programming, the new Cole-Parmer® Digital Gear ... is easy to operate for automated process applications. ... hands-free dispensing. The batch count function counts down ... or totalizer tracks amount dispensed across multiple cycles. ...
Breaking Biology Technology:Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2
... IRVINE, Calif., March 10 Diabetes will be ... plan to expand and improve healthcare coverage. ... located in Irvine, California, has developed a new ... of diabetes on our healthcare system.(Photo: ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... and Company 29th Annual Health Care Conference on Tuesday, ... parties may access a live webcast of the presentation ... is recommended that listeners log on 15 minutes early ...
... /PRNewswire-FirstCall/ -- Nektar Therapeutics, (Nasdaq: ... Robin, is scheduled to present at the upcoming Cowen and ... Marriott Copley Plaza on Monday, March 16, 2009 at 2:25 ... through a link posted on the Investor Relations, Events Calendar ...
Cached Biology Technology:Can Obama Plan Tackle Diabetes Crisis? Epinex Test Could Help 2
(Date:7/22/2014)... a cost-effectiveness analysis of commercial diet programs and pills, ... the best value for the money. The Jenny Craig ... the most expensive option tested, according to researchers at ... The findings, published in the June issue of the ... health and weight-loss benefits per dollar spent as insurance ...
(Date:7/22/2014)... squirrels have adapted to New York City,s human behaviour, ... better, than their fellow squirrels in the woods. , ... Environment & Agriculture, led the study that proved eastern ... urban environments and prevent unnecessary responses when humans acted ... footpath. , "As we rapidly increase the spread ...
(Date:7/22/2014)... a child,s lunch box and you,re likely to find that ... Those are the findings of a study conducted by researchers ... Tufts University and in the Department of Public Health and ... findings are published online ahead of print in the ... , Led by senior author Jeanne Goldberg, Ph.D., R.D., a ...
Breaking Biology News(10 mins):Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3New York squirrels are nuts about city life 2Room for improvement in elementary school children's lunches and snacks from home 2
... CINCINNATIWith the discovery of a RNA nano-scaffold that remains ... of Cincinnati (UC) have overcome another barrier to the ... Dane and Mary Louise Miller Endowed Chair and professor ... of Engineering and Applied Sciences report the construction of ...
... drilling rig exploded on April 20, 2010, in the ... planetary sciences at the University of Tennessee, Knoxville, grabbed all ... the Louisiana coast. Engel and dozens of scientists ... they knew would be needed once the oil began spilling ...
... of white LED bulbs, it turns out, suppresses melatonin 5 ... Sodium bulbs that give off an orange-yellow light. "Just as ... also be regulations and rules for the pollution stemming from ... University of Haifa. , "White" light bulbs that emit ...
Cached Biology News:Team finds stable RNA nano-scaffold within virus core 2UT researcher investigates Deepwater Horizon oil spill impact on coast 2Dangers of exposure to 'white' light 2Dangers of exposure to 'white' light 3
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
Biology Products: